Active, not recruitingPHASE2, PHASE3NCT05523167
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Studying Antisynthetase syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- EFG PH20 SC(biological)
- Enrollment
- 265 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Neuromuscular Research Center, Phoenix, Arizona, United States
- HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology, Scottsdale, Arizona, United States
- Attune Health Research, Inc, Beverly Hills, California, United States
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Profound Research LLC - Oceanside, Oceanside, California, United States
- University of California, Irvine, Orange, California, United States
- Eisenhower Medical Center, Rancho Mirage, California, United States
- Stanford Medicine Outpatient Center - Stanford Dermatology Clinic-Stanford University School of Medicine, Redwood City, California, United States
- California Pacific Medical Center - Sutter Health, San Francisco, California, United States
- Amyotrophic Lateral Sclerosis (ALS) Treatment Center,University of California San Francisco (UCSF), San Francisco, California, United States
- Denver Arthritis Clinic, Denver, Colorado, United States
- Yale Cancer Center-Yale University School Of Medicine, New Haven, Connecticut, United States
- Georgetown University Hospital, Washington D.C., District of Columbia, United States
- UF Health Rheumatology, Gainesville, Florida, United States
- Mayo Clinic, Jacksonville, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05523167 on ClinicalTrials.govOther trials for Antisynthetase syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07507877Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid ResponsivenessAin Shams University
- RECRUITINGPHASE2NCT07391605Descartes-08 in Autoantibody MyositisCartesian Therapeutics
- RECRUITINGNANCT07119255Effectiveness of PRP Pharmacopuncture for Chronic Neck Pain in Cervical Myofascial Syndrome of the Upper TrapeziusIndonesia University
- RECRUITINGEARLY PHASE1NCT06613490An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid ArthritisThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNANCT05726825Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic ShockHannover Medical School
- RECRUITINGNCT07126106Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU PatientsSisli Hamidiye Etfal Training and Research Hospital
- RECRUITINGNCT07089524A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for SepsisAin Shams University
- RECRUITINGNCT05984394Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung DiseaseCentral Hospital, Nancy, France